Laser mammography developer Imaging Diagnostic Systems announcedthis month that its stock will be listed on theNASDAQ stock exchange.The Plantation, FL, company, which is developing a mammographyscanner that uses laser light rather than x-rays, said the
Laser mammography developer Imaging Diagnostic Systems announcedthis month that its stock will be listed on theNASDAQ stock exchange.The Plantation, FL, company, which is developing a mammographyscanner that uses laser light rather than x-rays, said the moveshould help analysts and investors follow its stock more closely.IDSI's stock had been trading on the OTC Bulletin Board.
In other IDSI news, the company announced that it will conductphase I clinical trials for its CT Laser Mammography device atColumbia JFK Medical Center in Atlantis, FL. IDSI will submitan amendment to its existing investigational device exemption(IDE) to incorporate Columbia JFK as a clinical site. Once theamendment is accepted, IDSI will be able to use the hospital'sextensive database of patients with breast abnormalities.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.